Navigation Links
Simulated gene therapy
Date:4/29/2009

COLLEGE PARK, MARYLAND, April 29, 2009 -- In a recent issue of The Journal of Chemical Physics, published by the American Institute of Physics (AIP), a group of researchers at the University of California, Berkeley and Los Alamos National Laboratory describe the first comprehensive, molecular-level numerical study of gene therapy. Their work should help scientists design new experimental gene therapies and possibly solve some of the problems associated with this promising technique.

"There are several barriers to gene delivery," says Nikolaos Voulgarakis of Berkeley, the lead author on the paper. "The genetic material must be protected during transit to a cell, it must pass into a cell, it must survive the cell's defense mechanisms, and it must enter into the cell's guarded nucleus."

If all of these barriers can be overcome, gene therapy would be a valuable technique with profound clinical implications. It has the potential to correct a number of human diseases that result from specific genes in a person's DNA makeup not functioning properly -- or at all. Gene therapy would provide a mechanism to replace these specific genes, swapping out the bad for the good. If doctors could safely do this, they could treat or even cure diseases like cystic fibrosis, certain types of cancer, sickle cell anemia, and a number of rare genetic disorders.

Safety is a primary concern when working with gene therapy. Some of the first attempts at gene therapy used viruses to insert DNA into cells -- something that viruses naturally do anyway. Viruses can be dangerously toxic, however, and this fact was tragically demonstrated a decade ago when an 18-year-old boy enrolled in a gene therapy study had a massive immune reaction to the viruses used. He died just a few days into the treatment from multiple organ failure, precipitating an immediate halt to the trial.

Since then, many alternatives to viruses have emerged for use in gene therapy
'/>"/>

Contact: Jason Bardi
jbardi@aip.org
301-209-3091
American Institute of Physics
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Mice stressed in simulated weightlessness show organ atrophy
2. Worlds biggest heart model simulated at Université de Montréal
3. A new radiation therapy treatment developed for head and neck cancer patients
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UC health news: molecular pathway may predict chemotherapy effectiveness
6. MIT works toward safer gene therapy
7. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
8. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
9. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
10. Safe and effective therapy discovered for patients with protein-losing enteropathy
11. Ireland Cancer Center researchers advance stem cell gene therapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... , DURHAM, N.H. University of New Hampshire mi...taling $498,115 to advance understanding of the ac...tential to enrich nutrient-poor and contaminated s...ture (USDA) awarded Tisa, a professor of molecular...plore the symbiotic relationship between the bacte...
(Date:11/23/2009)... , , University of Southern California biomedical...s to develop a new tool to help clinicians disting...ry from chronic problems manageable with drugs and...catheters inserted into the arteries feeding the h... ("lumen") of these blood vessels, often revealing...
(Date:11/23/2009)... , Amphibians like frogs and toads have existed f...rs didn,t, but a new aquatic fungus is threatening...icle in the November issue of Microbiology Today ... (Bd), was found to be associated with waves of a...eastern Australia in the 1990,s. Bd infects over 3...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2H D Smith Promotes Leadership to Fill Two Senior Roles 51210 1H D Smith Promotes Leadership to Fill Two Senior Roles 51210 2ICU Medical Inc to Acquire Hospiras Critical Care Product Line 51206 1ICU Medical Inc to Acquire Hospiras Critical Care Product Line 51206 2ICU Medical Inc to Acquire Hospiras Critical Care Product Line 51206 3ICU Medical Inc to Acquire Hospiras Critical Care Product Line 51206 4ICU Medical Inc to Acquire Hospiras Critical Care Product Line 51206 5Study identifies potential fix for damaged knees 51203 1Study identifies potential fix for damaged knees 51203 2Study identifies potential fix for damaged knees 51203 3
...ngineers at MIT are developing a tiny sensor that ...dous gases, including toxic industrial chemicals a... current devices. , The researchers have taken th... spectrometry and shrunk them to fit in a device t... led by MIT Professor Akintunde Ibitayo Akinwande,...
...tes Xie Lab has published findings that begin to c...g stem cells within their cellular microenvironme...ays issue of Cell Stem Cell. , The Xie Lab demon...ovarian germline stem cells (GSCs), behaving like ...em cells for a position in the niche. They do so b...
... NY Cold Spring Harbor Laboratorys (CSHL) researc... by Joans Legacy: The Joan Scarangello Foundation ...nd CSHLs pioneering lung cancer research involving...e a trigger in non-small cell lung cancer, the lea..., The mutations, called epidermal growth factor r...
Other Biology News:MIT gas sensor is tiny, quick 2Cold Spring Harbor Laboratory's lung cancer research program awarded $100,000 grant 2
(Date:11/24/2009)...November24/PRNewswire-FirstCall/--deCODE,genetics,...noticefrom,theNasdaqStockMarketthattradinginthecom...09andaForm25-NSEwillbefiledwiththe,SecuritiesandEx...k,fromlistingonNasdaq,unlessthecompanyfilesanappea...hasfiledsuchanappeal,which,willstaythesuspensionan...
(Date:11/24/2009)...Newswire-Asia/--NODPharmaceuticalsInc.announced,th...entapplicationfor,itsnano-particleoraldeliveryorNO...tapproachtoincorporatepeptidesor,proteinsintobio-a...therwiseadministeredasinjections.NODtechnologyisap...ulardrugssuchasinsulin,interferon,growthhormone,e...
(Date:11/24/2009)...The FBI recently approved the Promega PowerPlex 16...n or generating DNA records for the National DNA I...I USA (PRWEB) -- The FBI recently approved the Pro...ratories participating in, or generating DNA recor... currently contains more than seven million profil...
(Date:11/24/2009)...09/PRNewswire-FirstCall/--ArenaPharmaceuticals,Inc...heduledtopresentatthePiperJaffray21stAnnualHealthC...e(8:30a.m.PacificTime)attheNewYorkPalaceHotelinNew...iveOfficer,isscheduledtoprovideanoverviewofthecomp...grams. ,, Aliveaudiowebcastofthepresentationwil...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...ransfer Paves the Way for the Phase III Clinical D...00 in Developing Countries, LEUVEN, Belgium, Sept..., a biotechnology company focused on vascular dise...the technology transfer to Bharat,Biotech Internat...re of,THR-100, a novel variant of Recombinant Stap...
...EIJING, Sept. 3 /Xinhua-PRNewswire-FirstCall/ -- C...asdaq: CMED ), a leading China-based,medical devi... advanced in-,vitro diagnostic products and high i... today announced that it will participate in Credi...a Day. Location: Shenzhen, China Date:...
...ARIS, September 2 Sanofi-aventis announced,today ...IMI 25 and STEEPLE,studies confirm clear net clini...vation myocardial infarction (STEMI) for Lovenox(R...IMI 25 and STEEPLE one year results were presented...f Cardiology (ESC) Congress in,Vienna, Austria. E...
Other Biology Technology:ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
...D.471. Immunogen: Synthetic peptide derived from ...Specificity: Specific for the junctophilin-1 prote...rain and skeletal muscle homogenates frozen mouse ... Western blotting Immunohistochemistry(froz) Immun...
Mouse Anti-Human Laminin beta-1 / gamma-1 complex Monoclonal Antibody, Unconjugated, Clone 612C10 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-JIP 1 Polyclonal Antibody, Unconjugated from BioVision
Mouse Anti-Mouse XBP-1 Monoclonal Antibody, Unconjugated, Clone F-4 from Santa Cruz Biotechnology, Inc.
Biology Products: